A team of highly published, ICU critical care physician/scholars have conducted a comprehensive analysis of the rapidly accumulating scientific study data from centers around the world supporting the efficacy of a repurposed oral medication. The team will announce the results of its research that demonstrates the consistent, reproducible, and high effectiveness of this safe, inexpensive, and globally available oral agent in both the prevention and treatment of COVID-19.
The physicians will also call for immediate action from national health authorities to conduct a swift review of these data; with the goal of then being able to issue an urgent public health alert with recommendations for widespread distribution of this therapeutic that can significantly impact the current surge in COVID-19 infections.
When: Friday morning, December 4, at 10:30 am CST
Where: United Memorial Medical Center in Houston, Texas
510 West Tidwell Road, 77091
Webinar registration: https://us02web.zoom.us/webinar/register/WN_TrQi8iUvTeC_Gf_s6Z2jqA
Who: Joe Varon, M.D., FCCP, FCCM
− Chief of Staff and Chief of Critical Care Services at United Memorial Medical Center and United General Hospital
− Former Chief of Staff at University General Hospital
− Professor of Acute and Con+nuing Care at the University of Texas Health Science Center, CAP, Department of Medicine, Baylor College of Medicine
− Professor of Medicine and Surgery, UAT, UABC, UNE, USON, UPAEP, Mexico
Paul Marik, M.D., FCCM, FCCP
− Board certified in Internal Medicine, Cri+cal Care Medicine, Neurocritical Care and Nutrition Science
− Professor of Medicine (with tenure) and Chief of the Division of Pulmonary and Critical Care Medicine, at Eastern Virginia Medical School in Norfolk, Virginia
− Author of more than 450 peer-reviewed journal articles, 80 book chapters, and four critical care books
− Cited over 36,000 times in peer-reviewed publications
− Delivered more than 350 lectures at international conferences and visiting professorships
− Recipient of numerous teaching awards including ‘National Teacher of the Year’ by the American College of Physicians in 2017
− The second most published critical care doctor in the world
Pierre Kory, M.D., M.P.A.
− Associate Professor of Medicine, Board Certified in Critical Care, Pulmonary Diseases, and Internal Medicine
− Advocate Aurora Critical Care Service, Aurora St. Luke’s Medical Center, Milwaukee,WI
− Former Chief of the Critical Care Service and Medical Director of the Trauma and Life Support Center at the University of Wisconsin
− Senior editor of the best-selling textbook, ‘Point of Care Ultrasound’ now translated into 6 languages,
published expert on the use of therapeutic hypothermia after cardiac arrest and the efficacy of intravenous
ascorbic acid in the treatment of severe infections and septic shock
Drs. Varon, Marik, and Kory are founding members of the Frontline COVID-19 Critical Care Alliance (FLCCC) a 501(c)(3) nonprofit organization formed by a group of Critical Care physician/scholars — with the academic support of allied physicians from around the world — formed in March 2020, to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness. The FLCCC doctors share decades of experience in hospital ICUs and have published more than 1,000 scientific studies in leading medical journals. (The FLCCC is not associated in any way with the group called ‘America’s FrontlineDoctors’.)
If you want to know more about the FLCCC Alliance please regard our “About” section on www.flccc.net, in particular the “FLCCC Alliance Story.”
In addition our home page contains Scientific Reviews and many links to scientific studies that provide the medical evidence in support of our prophylaxis & treatment protocols for Covid-19.
FLCCC Alliance – Mission Statement and ObjecOves
Formed by leading critical care specialists in March 2020, at the beginning of the Coronavirus pandemic, the ‘Front Line COVID-19 Critical Care Alliance’ is now a 501(c)(3) non-profit organization dedicated to developing highly effective treatment protocols to prevent the transmission of COVID-19 and to improve the outcomes for patients ill with the disease.
We are dedicated to
− Reviewing all emerging published medical literature on COVID-19 from in-vitro, animal, clinical, and epidemiologic studies.
− Developing effetive treatment protocols for COVID-19 that evolve by incorporating newly identified, applicable therapeutic and pathophysiologic insights.
− Educating physicians on safe and effective treatment approaches to all phases of COVID-19, from disease prevetion strategies to the use of our combination-based therapy protocols in both early stage (I-MASK+) and hospitalized patients (MATH+).
− Improving outcomes for people impacted by COVID-19 disorders through preventive and treatment strategies designed to optimize health.
− Teaching the public ways to prevent transmission of the virus and to advocate for the best possible care.
− Coordinating and accelerating the formation of research studies that will support effective prevention and therapeutic treatments for all impacted by COVID-19
We accomplish these goals by sponsoring high quality medical education for both the public and health care providers, via the publication of scientific manuscripts, media interviews, and medical lectures for medical providers and the public.
For more information about the FLCCC Alliance, the I-Mask+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 and the MATH+ Hospital Treatment Protocol for COVID-19, please visit www.flccc.net